SOURCE: TheraBiogen, Inc.

June 01, 2011 08:45 ET

TheraBiogen, Inc. Announces Launch of Third Product, Migraine Relief, for Its TheraMax® Product Line

NEW YORK, NY--(Marketwire - Jun 1, 2011) - TheraBiogen, Inc. (OTCBB: TRAB) today announced the launch of its third product: TheraMax® Migraine Relief.

TheraBiogen has been selling TheraMax® Cold & Flu Relief and TheraMax® Allergy Relief since the beginning of the 2010 Fall Season for cold and flu relief. TheraMax® products are homeopathic nasal sprays that do not contain zinc. TheraBiogen, Inc. is launching the third product from its development pipeline, TheraMax® Migraine Relief nasal spray. This new product is scheduled for delivery before the end of 2011. Note that TheraMax® Migraine Relief is not for regular headaches, but is designed for the migraine headaches that millions suffer from every year. This delivery system is ideal as it is designed to have a direct effect and is absorbed immediately. There is no other homeopathic all natural nasal delivery of Migraine Relief available.

TheraMax is available for purchase in thousands of locations from Rite-Aid, Walgreens Miami South District, Hannaford Supermarkets, Discount Drug Marts and Big Y Supermarkets. For more information on TheraMax visit our website www.theramaxrelief.com or our Facebook page at facebook.com/theramaxnasalspray.

About TheraBiogen, Inc.
TheraBiogen, Inc. is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com.

Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.

Contact Information

  • Company Contact:
    TheraBiogen, Inc.
    Kelly T. Hickel
    Chairman and CEO
    646-808-3095
    Email Contact